Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...
JournalofAccountancy17h
PCAOB withdraws proposed rules requiring extensive firm and engagement metrics
The AICPA had urged the SEC to refrain from approving the rules, warning they would “pose significant challenges” to small and midsize firms. An AICPA statement said that the “PCAOB’s decision not to ...
Super Micro to file delayed annual report by February deadline, shares rise
Super Micro Computer said on Tuesday it believes it will be able to file delayed annual and quarterly reports with the U.S.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Princeton Daily Clarion6d
D of I Circle 151 prepares for April state convention
The Daughters of Isabella, Haubstadt Circle 151, convened at the Knights of Columbus Hall in Haubstadt Jan. 20 for a regular meeting. The meeting was opened by Regent ...
lifesciencesipreview6d
Fed Circ raises ‘gamesmanship’ fears in rare patent term dispute
Oral hearings heard the USPTO side with MSD (Merck) over a term extension for a reissued patent, in a case set to have huge implications for pharma market exclusivity, reports Marisa Woutersen.